Alkem Laboratories Limited reported a 6.1% rise in consolidated net profit to ₹23,511.6 million for FY26, with revenue increasing to ₹147,122.7 million. The board recommended a final dividend of ₹10 per share and fixed the record date as August 7, 2026. Exceptional items for the year included provisions for real estate impairment and Labour Codes.
Alkem Laboratories Limited reported a consolidated net profit of ₹23,511.6 million for the financial year ended March 31, 2026, representing a 6.1% increase from ₹22,153.8 million in the prior year. Revenue from operations for FY26 stood at ₹147,122.7 million, compared to ₹129,645.2 million in FY25. The company’s board has recommended a final dividend of ₹10 per equity share of ₹2 each, pending approval at the upcoming Annual General Meeting.
For the quarter ended March 31, 2026, the company recorded a consolidated net profit of ₹2,511.1 million, a decline from ₹3,223.9 million in the corresponding quarter of the previous year. Revenue from operations for Q4FY26 was ₹36,033.2 million, up from ₹31,437.5 million in Q4FY25. The board approved the standalone and consolidated audited financial results for the quarter and year ended March 31, 2026.
The financial results included exceptional items totaling ₹1,748.3 million for the year. These comprised a provision of ₹747 million for impairment of real estate investments and an estimated liability of ₹1,130.6 million related to the Labour Codes, including gratuity and leave encashment costs. Additionally, a gain of ₹142.9 million was recognized from the sale of the Indore facility. The auditors, Deloitte Haskins & Sells LLP, issued an unmodified opinion on the financial results.
The board fixed August 7, 2026, as the record date for the payment of the final dividend. If declared, the dividend will be paid on and from September 1, 2026. The 52nd Annual General Meeting is scheduled for August 27, 2026, with a cut-off date of August 20, 2026. The board also approved the re-appointment of Mrs. Madhurima Singh as an Executive Director for a term of five years effective from December 20, 2026.
Consolidated Financial Results for FY26
Particulars Year ended 31.03.2026 (₹ in Million) Year ended 31.03.2025 (₹ in Million) Revenue from Operations 147,122.7 129,645.2 Total Income 152,956.2 134,582.6 Total Expenses 122,499.0 109,312.3 Profit before Tax 28,708.9 25,270.3 Net Profit for the period 23,511.6 22,153.8 Earnings Per Share (Basic) (₹) 192.51 181.11
Standalone Financial Results for FY26
Particulars Year ended 31.03.2026 (₹ in Million) Year ended 31.03.2025 (₹ in Million) Revenue from Operations 96,639.1 88,134.4 Total Income 102,190.8 93,205.0 Total Expenses 75,533.7 70,169.6 Profit before Tax 25,226.2 23,035.4 Net Profit for the period 22,820.9 22,808.9 Earnings Per Share (Basic) (₹) 190.87 190.77
Alkem Laboratories Limited has scheduled a one-on-one meeting with SBI Mutual Fund on May 29, 2026, in Mumbai. The interaction aims to engage with the institutional investor regarding the company's operations and performance.
The disclosure was made in reference to the relevant provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company specified that the engagement will be an in-person meeting.
Meeting Details
The following table outlines the specifics of the scheduled interaction:
Date Analyst / Investor Type of Meeting Nature of Meeting Location May 29, 2026 SBI Mutual Fund In-person One-on-One meet Mumbai
The company noted that the schedule for the aforementioned meeting is subject to change due to exigencies on the part of the investor or the company. The intimation was signed by Manish Narang, President – Legal, Company Secretary & Compliance Officer.
We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.
Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.
We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.
Disclaimer:
The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.
This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.
The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.
We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.
This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.
By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.
We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.